Search research articles
Contact Us
Filters
Showing results (51-60 of 231) with videos related to
Page
of 24
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
June 24, 2023
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
Pieter Sonneveld, Paul G Richardson, Heinz Ludwig, et al.
European Journal of Haematology
|
May 1, 2024
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial
Maria-Victoria Mateos, Monika Engelhardt, Xavier Leleu, et al.
British Journal of Haematology
|
July 14, 2016
Multiple myeloma: patient outcomes in real-world practice
Kwee Yong, Michel Delforge, Christoph Driessen, et al.
British Journal of Haematology
|
June 14, 2016
Multiple myeloma: practice patterns across Europe
Marc S Raab, Michele Cavo, Michel Delforge, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 23, 2021
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Cristina Gasparetto, Kristian M Bowles, Al-Ola Abdallah, et al.
Haematologica
|
November 3, 2009
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients
Bruno Paiva, Maria-Belén Vidriales, Jose J Pérez, et al.
Advances in Therapy
|
June 28, 2022
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
Thierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Hemasphere
|
February 8, 2023
Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
Enrique M Ocio, Sara Bringhen, Joaquin Martinez-Lopez, et al.
Advances in Therapy
|
March 5, 2022
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
Thierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Hemasphere
|
November 7, 2024
30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
Enrique M Ocio, Aurore Perrot, Philippe Moreau, et al.
Page
of 24
Search research articles
Search
Showing results (51-60 of 231) with videos related to
Sort By:
Page
of 24
Clinical Lymphoma, Myeloma & Leukemia
|
June 24, 2023
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
Pieter Sonneveld, Paul G Richardson, Heinz Ludwig, et al.
European Journal of Haematology
|
May 1, 2024
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial
Maria-Victoria Mateos, Monika Engelhardt, Xavier Leleu, et al.
British Journal of Haematology
|
July 14, 2016
Multiple myeloma: patient outcomes in real-world practice
Kwee Yong, Michel Delforge, Christoph Driessen, et al.
British Journal of Haematology
|
June 14, 2016
Multiple myeloma: practice patterns across Europe
Marc S Raab, Michele Cavo, Michel Delforge, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
September 23, 2021
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Cristina Gasparetto, Kristian M Bowles, Al-Ola Abdallah, et al.
Haematologica
|
November 3, 2009
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients
Bruno Paiva, Maria-Belén Vidriales, Jose J Pérez, et al.
Advances in Therapy
|
June 28, 2022
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
Thierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Hemasphere
|
February 8, 2023
Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
Enrique M Ocio, Sara Bringhen, Joaquin Martinez-Lopez, et al.
Advances in Therapy
|
March 5, 2022
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
Thierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Hemasphere
|
November 7, 2024
30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
Enrique M Ocio, Aurore Perrot, Philippe Moreau, et al.
Page
of 24